Drug intelligence / Profile preview

HDT-211

Development stage: Unknown
Lead developer: HDT Bio
Modality: Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics

Overview

HDT-211 is an investigational oncology drug developed by HDT Bio for the treatment of glioblastoma. It leverages HDT Bio's proprietary LION™ technology and AMPLIFY platform, which utilizes self-replicating replicon RNA (repRNA) delivered via a nanoparticle formulation. The drug is designed to stimulate T cell-mediated immunological memory responses to combat cancer. This approach aims to harness the immune system to treat or prevent cancer by inducing a localized, robust immune response against disease-specific antigens.

Targets

TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on HDT-211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDT-211.

Explore the full profile